Greenwich LifeSciences price to book ratio GLSI

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 75.5×
6-year median: 21.4×
Against its 6-year history: 77th; percentile: 0 is its lowest day, 100 its highest
6-year range: 4.2× to 191×
Peer median: 2.2×

Greenwich LifeSciences' price to book ratio is 75.5× as of Oct 23, 2026.

That is above its 6-year median of 21.4×, higher than on 77% of days in the last 6 years.

Over that time it ranged from 4.2× in May 2022 to 191× in Jan 2026.

The median for 10 large drugmakers of a similar size is 2.2×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	75.5×	36.2×	191×
2025	131×	23.3×	131×
2024	30.3×	12.3×	43.4×
2023	15.3×	9.7×	17.4×
2022	12.7×	4.2×	12.7×
2021	11.2×	11.2×	101×
2020	94.1×	13.7×	144×

Against its peers

Companies in Drug Manufacturers - General nearest Greenwich LifeSciences' size, closest first, today.

Company	Price to book ratio
GLSIGreenwich LifeSciences	75.5×
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
LFVNLifevantage	2.2×
ABUSArbutus Biopharma	3.2×
SPROSpero Therapeutics	1.5×
Peer median	2.2×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Greenwich LifeSciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.